Thilo Bracht
Thilo Bracht
Medizinisches Proteom-Center, Ruhr-University Bochum, Knappschaftskrankenhaus Bochum
Verified email at
Cited by
Cited by
Label-free quantification in clinical proteomics
DA Megger, T Bracht, HE Meyer, B Sitek
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1834 (8), 1581-1590, 2013
Comparison of label-free and label-based strategies for proteome analysis of hepatoma cell lines
DA Megger, LL Pott, M Ahrens, J Padden, T Bracht, K Kuhlmann, ...
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844 (5), 967-976, 2014
Proteomic differences between hepatocellular carcinoma and nontumorous liver tissue investigated by a combined gel-based and label-free quantitative proteomics study
DA Megger, T Bracht, M Kohl, M Ahrens, W Naboulsi, F Weber, ...
Molecular & Cellular Proteomics 12 (7), 2006-2020, 2013
Analysis of Disease-Associated Protein Expression Using Quantitative Proteomics Fibulin-5 Is Expressed in Association with Hepatic Fibrosis
T Bracht, V Schweinsberg, M Trippler, M Kohl, M Ahrens, J Padden, ...
Journal of proteome research 14 (5), 2278-2286, 2015
Identification of novel biomarker candidates for the immunohistochemical diagnosis of cholangiocellular carcinoma
J Padden, DA Megger, T Bracht, H Reis, M Ahrens, M Kohl, M Eisenacher, ...
Molecular & Cellular Proteomics 13 (10), 2661-2672, 2014
Identification of a soluble guanylate cyclase in RBCs: preserved activity in patients with coronary artery disease
MM Cortese-Krott, E Mergia, CM Kramer, W Lückstädt, J Yang, G Wolff, ...
Redox Biology 14, 328-337, 2018
A practical data processing workflow for multi-OMICS projects
M Kohl, DA Megger, M Trippler, H Meckel, M Ahrens, T Bracht, F Weber, ...
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1844 (1), 52-62, 2014
Spatial and molecular resolution of diffuse malignant mesothelioma heterogeneity by integrating label-free FTIR imaging, laser capture microdissection and proteomics
F Großerueschkamp, T Bracht, HC Diehl, C Kuepper, M Ahrens, ...
Scientific reports 7 (1), 44829, 2017
Quantitative tissue proteomics analysis reveals versican as potential biomarker for early-stage hepatocellular carcinoma
W Naboulsi, DA Megger, T Bracht, M Kohl, M Turewicz, M Eisenacher, ...
Journal of proteome research 15 (1), 38-47, 2016
An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma
A Lollies, S Hartmann, M Schneider, T Bracht, AL Weiss, J Arnolds, ...
Leukemia 32 (1), 92-101, 2018
Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients
T Bracht, C Mölleken, M Ahrens, G Poschmann, A Schlosser, ...
Journal of Translational Medicine 14 (1), 1-9, 2016
The α2β1 integrin‐specific antagonist rhodocetin is a cruciform, heterotetrameric molecule
JA Eble, S Niland, T Bracht, M Mormann, J Peter-Katalinic, G Pohlentz, ...
The FASEB Journal 23 (9), 2917-2927, 2009
Integrated Fourier transform infrared imaging and proteomics for identification of a candidate histochemical biomarker in bladder cancer
KE Witzke, F Großerueschkamp, H Jütte, M Horn, F Roghmann, ...
The American journal of pathology 189 (3), 619-631, 2019
Eukaryotic elongation factor 2 is a prognostic marker and its kinase a potential therapeutic target in HCC
LL Pott, S Hagemann, H Reis, K Lorenz, T Bracht, T Herold, BV Skryabin, ...
Oncotarget 8 (7), 11950, 2017
A structured proteomic approach identifies 14-3-3Sigma as a novel and reliable protein biomarker in panel based differential diagnostics of liver tumors
H Reis, C Pütter, DA Megger, T Bracht, F Weber, AC Hoffmann, S Bertram, ...
Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics 1854 (6), 641-650, 2015
Systematic comparison of label-free, SILAC, and TMT techniques to study early adaption toward inhibition of EGFR signaling in the colorectal cancer cell line DiFi
M Stepath, B Zülch, A Maghnouj, K Schork, M Turewicz, M Eisenacher, ...
Journal of proteome research 19 (2), 926-937, 2019
Immunohistochemical markers distinguishing cholangiocellular carcinoma (CCC) from pancreatic ductal adenocarcinoma (PDAC) discovered by proteomic analysis of microdissected cells
J Padden, M Ahrens, J Kälsch, S Bertram, DA Megger, T Bracht, ...
Molecular & Cellular Proteomics 15 (3), 1072-1082, 2016
C19orf66 is an interferon-induced inhibitor of HCV replication that restricts formation of the viral replication organelle
V Kinast, A Plociennikowska, T Bracht, D Todt, RJP Brown, T Boldanova, ...
Journal of hepatology 73 (3), 549-558, 2020
BioInfra. Prot: A comprehensive proteomics workflow including data standardization, protein inference, expression analysis and data publication
M Turewicz, M Kohl, M Ahrens, G Mayer, J Uszkoreit, W Naboulsi, ...
Journal of biotechnology 261, 116-125, 2017
Analysis of U2 small nuclear RNA fragments in the bile differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders
A Baraniskin, S Nöpel-Dünnebacke, B Schumacher, C Gerges, T Bracht, ...
Digestive diseases and sciences 59, 1436-1441, 2014
The system can't perform the operation now. Try again later.
Articles 1–20